Oncology

Automated texts may also lessen the workload on nurses.

COTA’s real-world data and Kite's drug development pipeline will complement single-arm clinical trials to accelerate cancer research benefiting patients.

Screening and some care have been canceled or deferred. Will more illness and deaths result?

The decision by Roche comes shortly after AstraZeneca withdrew the bladder cancer indication for durvalumab (Imfinzi).

NCI Director Norman Sharpless discussed deferred care, missed screening and his future at the institute in an interview with Managed Healthcare Executive.

Adjustments to payment models are beginning to take social determinants into account.

One of the new treatments available is a CAR-T cell therapy to treat relapsed or refractory large B-cell lymphoma.

Payer strains now top the list of stressors facing oncologists, with prior authorization as the most-cited source of that payer stress.

The pandemic has led to the adoption of telehealth and greater access to care through apps.

The organizations give recommendations on how to get patients to receive the care they need.

FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).

Deposing the ‘Emperor of All Maladies’ will take a diverse toolkit, not a single moonshot.

New treatment for metastatic HER2-positive breast cancer is called Margenza.

More oncologists are experiencing burnout due to the loss of face-to-face interactions with patients, according to a report from Cardinal Health Specialty Solutions.

Drug and diagnostic approvals and biosimilars news were popular with readers.

How the pandemic has accelerated innovation, and how CVS Health is preparing to delivery vaccines for COVID-19.

The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.

The second mRNA vaccine, which does not need the extreme refrigeration of the Pfizer product, began rolling out of a warehouse in Mississippi early Sunday. Friday brought other late-year approvals in cancer treatment.

Prostate cancer is often “indolent,” so it can be monitored and not treated right away.

After positive Phase 3 trial results, Karyopharm Therapeutics expects FDA to clear Xpovio.

A filing for a bispecific antibody, and more time after a therapy gets more responses.

The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Public health policies and treatment advances have made a difference.

Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.